Katherine Petti is currently seconded to Fox News and is not handling Williams & Connolly client matters.
Katherine Petti focuses on complex civil litigation, especially in the area of media law (including the defense of a national television news organization in the most significant defamation case to go to trial in years) and products liability. She has also worked in the areas of trade secrets litigation, securities matters, FDCPA law, and government contracts. She has practiced in the trial and appellate levels of state and federal courts, as well as in domestic and international arbitration proceedings.
Katherine has significant state and federal experience in all aspects of litigation and arbitration, from motions to dismiss, to fact development, through the trial stage of litigation (including a multi-billion-dollar jury trial and multi-billion-dollar patent arbitration), and finally, to the appellate level and cert-stage and merits stage of the Supreme Court.
Katherine has been named a Rising Star by Super Lawyers for 2018 through 2020. For her work at the Supreme Court, Katherine was part of the team named "Legal Lions" by Law360 after the firm’s win at the Supreme Court in Midland Funding v. Johnson.
A native of Atlanta, Georgia, Katherine graduated with honors from Harvard College and Harvard Law School. Katherine joined Williams & Connolly in 2014 after a clerkship in Ann Arbor, Michigan with the Honorable Judge Raymond Kethledge of the United States Court of Appeals for the Sixth Circuit.
Though all cases vary and none is predictive, Katherine’s experience includes:
- Representing a national television network in two matters alleging defamation and related claims
- Defense of national television news organization in defamation and product disparagement lawsuit seeking more than $1 billion
- Successfully represented Midland Funding in a case regarding the FDCPA and Bankruptcy Code, in the Supreme Court in OT 2016 (Midland Funding v. Johnson).
- Served as counsel in a major international patent licensing arbitration, which was tried in 2015 before a three-member panel, relating to standard essential patents and products with billions of dollars in revenue
- Represented Pfizer Inc. in a securities fraud class action resulting from decrease in stock price upon announcement of resolution of certain government investigations. The case was resolved one week before trial.